Dunhill Financial’s Roivant Sciences ROIV Stock Holding History

Dunhill Financial’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217	Hold	6	–	–	﹤0.01%	1252
2026 Q1	$169	Hold	6	–	–	﹤0.01%	1288
2025 Q4	$133	Buy	+6	New	+$118	﹤0.01%	1259

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Dunhill Financial's ROIV Position: Q2 2026 in Review

Dunhill Financial held its Roivant Sciences (ROIV) position steady in Q2 2026 at 6 shares worth $217. The position accounts for ﹤0.01% of the portfolio, ranked #1252.

Dunhill Financial first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Dunhill Financial held 6 shares of Roivant Sciences worth $217 as of Q2 2026.
Dunhill Financial left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1252 holding.
Dunhill Financial first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.